Korro Bio, Inc. KRRO
We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. We are generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient change to a single nucleoside (adenosine to an inosine edit). By editing RNA instead of DNA, we are expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. We use an oligonucleotide-based approach and expect to bring our medicines to patients by leveraging our proprietary platform with precedented delivery modalities, including N-acetylgalactosamine, or GalNAc, -conjugated delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. However, the scientific evidence to support the feasibility of developing lead candidates using our RNA editing technology is both preliminary and limited. Moreover, regulators have not yet established any definitive guidelines related to overall development considerations for RNA editing therapies and limited clinical data has been generated to date.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $2.3M | $0 | $0 | $14.1M | $37.0M | $28.9M | — | — | — |
| R&D | $65.6M | $63.6M | $57.2M | $42.2M | $60.9M | $37.4M | $18.8M | $11.9M | $12.0M | — |
| SG&A | $28.2M | $30.5M | $27.3M | $16.8M | $37.2M | $27.1M | $14.8M | $7.1M | $4.3M | — |
| Total operating expenses | $128.2M | $94.2M | $84.5M | $59.0M | $98.1M | $64.5M | $49.6M | $18.9M | $16.3M | — |
| Operating income | -$121.9M | -$91.9M | -$84.5M | -$59.0M | -$84.0M | -$27.6M | -$20.7M | -$18.9M | -$16.3M | — |
| Interest expense | — | — | $0 | $118.0K | $764.0K | $0 | $1.8M | $106.0K | $174.0K | — |
| Pre-tax income | -$116.6M | -$83.4M | -$81.1M | -$58.0M | -$84.7M | -$26.5M | -$18.7M | — | — | — |
| Income tax | $637.0K | $141.0K | $27.0K | $10.0K | $15.0K | $35.0K | $0 | — | — | — |
| Net income | -$117.3M | -$83.6M | -$81.2M | -$58.0M | -$84.7M | -$26.5M | -$18.7M | -$19.2M | -$20.2M | — |
| EPS, basic | -12.48 | -9.37 | -53.08 | -227.42 | — | — | — | — | — | — |
| EPS, diluted | -12.48 | -9.37 | -53.08 | -227.42 | -2.47 | -0.82 | -2.29 | -12.53 | -28.79 | — |
| Shares, diluted (wtd. avg.) | 9.4M | 8.9M | 1.5M | 255,175 | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $21.8M | $55.6M | $36.6M | $36.3M | $79.6M | $220.3M | $200.2M | $42.2M | — | — |
| Short-term investments | $53.3M | $70.5M | $0 | $18.9M | $51.1M | — | $17.2M | — | — | — |
| Total current assets | $82.4M | $131.5M | $172.7M | $57.1M | $134.7M | $225.1M | $221.4M | $42.9M | — | — |
| Property, plant and equipment | $8.2M | $27.7M | $15.7M | $9.9M | $5.5M | $7.3M | $1.8M | $1.5M | — | — |
| Total assets | $113.5M | $226.2M | $221.7M | $73.7M | $185.4M | $264.7M | $223.2M | $44.5M | — | — |
| Accounts payable | $1.7M | $4.0M | $7.3M | $2.6M | $2.7M | $5.5M | $1.2M | $1.9M | — | — |
| Short-term debt | — | — | — | $10.0M | $833.0K | — | — | — | — | — |
| Total current liabilities | $11.9M | $15.0M | $19.5M | $8.7M | $11.4M | $26.6M | $52.8M | $3.8M | — | — |
| Long-term debt | — | — | — | — | — | — | $180.0K | $349.0K | — | — |
| Total liabilities | $62.1M | $65.8M | $51.8M | $8.9M | $54.5M | $72.2M | $55.9M | $4.1M | — | — |
| Retained earnings | -$383.8M | -$266.6M | -$183.0M | -$101.8M | -$180.1M | -$95.4M | -$68.9M | -$49.1M | — | — |
| Total equity | $51.4M | $160.4M | $169.9M | -$99.0M | -$42.2M | $192.5M | $167.4M | -$48.3M | -$29.6M | -$9.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$78.6M | -$60.1M | -$67.3M | -$53.6M | -$76.1M | -$45.2M | $34.2M | -$17.0M | -$14.6M | — |
| Depreciation and amortisation | $4.3M | $3.6M | $3.6M | $2.5M | $2.8M | $1.1M | $813.0K | $654.0K | $531.0K | — |
| Stock-based compensation | — | — | — | $19.8M | $21.8M | $10.0M | $3.6M | $455.0K | $91.0K | — |
| Capital expenditure | $518.0K | $17.9M | $7.8M | $5.1M | $2.9M | $6.7M | $1.1M | $436.0K | $1.9M | — |
| Investing cash flow | $44.0M | -$123.3M | $11.2M | $11.1M | -$66.1M | $10.4M | -$18.3M | -$436.0K | -$1.9M | — |
| Financing cash flow | $685.0K | $69.4M | $187.8M | $18.0K | $1.4M | $56.7M | $142.0M | $41.7M | $28.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-157895.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $28.9M | $37.0M | $14.1M | $0 | $0 | $2.3M | $6.4M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | — | -$20.2M | -$19.2M | -$18.7M | -$26.5M | -$84.7M | -$58.0M | -$81.2M | -$83.6M | -$117.3M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Results announced Item 2.02
- Unregistered share sale Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |